PTC Therapeutics | Pioneers in Rare Disease Treatments
PTC Therapeutics pioneers pharmaceutical science to transform lives and treat rare diseases, like Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, Huntington's Disease, Leukemia, …
About PTC Therapeutics - Treatments for Rare Diseases
Learn about PTC Therapeutics, a global biopharmaceutical company. We are fueled by science, and committed to transforming the lives of patients with rare diseases.
Our Pipeline - PTC Therapeutics
PTC has been a pioneer in the development of breakthrough rare disease therapies, delivering a number of firsts for patients who previously had no other treatment options. Our strategy …
Our Science - PTC Therapeutics
We have focused our research efforts on two scientific platforms—splicing and inflammation and ferroptosis — where PTC has unique expertise to discover and advance to the clinic …
Newsroom | The Latest on PTC Therapeutics
Read the latest updates on innovations, research, rare disease treatments, business & finance, and community relations at PTC Therapeutics.
Investors | PTC Therapeutics, Inc.
Dec 19, 2024 · The Investor Relations website contains information about PTC Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Press Releases - PTC Therapeutics, Inc.
WARREN, N.J. , Nov. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease …
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA …
WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the …
Therapeutic Areas - PTC Therapeutics
We are deeply committed to patients living with rare diseases who have little-to-no treatment options, and this passion fuels and inspires us. Our commercial and development efforts are …
PTC Therapeutics Announces FDA Approval of AADC Deficiency …
WARREN, N.J., Nov. 13, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its …